Golden
OncoSenX

OncoSenX

OncoSenX is a spinout company of Oisin Biotechnologies, formed to develop programmable suicide gene therapy to kill cancerous cells.

OncoSenX uses the transcriptional activity, or gene activity, of solid tumors to target them using a lipid nanoparticle and plasmid DNA. Their system aims to induce apoptosis, a type of cell death, in cancerous cells. The plasmid DNA codes for an inducible death protein controlled by a DNA element called a promoter which is active the target cancer cells. 



Their initial treatment targets tumors with elevated levels of p53 transcription factors. Cells are killed by apoptosis due to induction of Caspase-9, a critical enzyme in the apoptotic pathway. The DNA payload system implements logic gates, IF/OR/AND, allowing precise targeting of cell populations based on their genetic activity and leaving adjacent cells unharmed. 



The delivery system uses a patented lipid nanoparticle (LNP) as a transfection agent to deliver the non-integrating DNA plasmid into cancer cells. Non-Human Primate Studies began in August, 2017 by RxGen which showed no visible toxicity at doses ten times the normal human dose, but full analysis is yet to be completed. 



OncoSenX partners with Oisin Biotechnologies, Entos Pharmaceuticals, The Methuselah Fund, The Methuselah Foundation, The SENS Research Foundation and the laboratory of Dr. John Lewis at University of Alberta, Canada. Lewis is co-founder of OncoSenX along with Matthew Scholz.

Timeline

People

Name
Role
Related Golden topics

ERIC GARCIA

Chief Operating Officer



GARY C. HUDSON

Executive Chairman



JOHN D. LEWIS, PhD

Chief Science Officer, Co-Founder



MATTHEW SCHOLZ

Chief Executive Officer, Co-Founder



STEPHEN HILBERT

President of Corporate Development



Further reading

Title
Author
Link
Type







Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References